Figure 4 Example of a patients with CUP

Slides:

Advertisements

Similar presentations

Slides last updated: October There are two main types of lung cancer 1 1.Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review,

Advertisements

Defining Epidermal Growth Factor Receptor exon 20 mutant sensitivity to tyrosine kinase inhibition Danny Rayes.

Epidermal Growth Factor Receptor Mutation in a Patient with Squamous Cell Carcinoma of the Lung: Who Should Be Tested Case Rep Oncol 2013;6:

Algorithm for adenocarcinoma diagnosis in small biopsies and/or cytology. Step 1: When positive biopsies (fiberoptic bronchoscopy [FOB], transbronchial.

Improved diagnosis, therapy and outcomes for patients with CUP

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Patient Case 1 Patient Case 1: PET/CT Scan.

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.

Figure 2 Multiscale modelling in oncology

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Monitoring clonal evolution using liquid biopsies

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 5 Identification of mucinous carcinoma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 1 Proposed treatment algorithm for advanced gastroesophageal cancer based on publish recommendations Figure 1 | Proposed treatment algorithm for.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 CAR-T-cell design

Figure 2 Examples of histopathological validation

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Figure 2 The association between CD8+ T‑cell density of the tumour

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Therapeutic targeting of the B-cell receptor (BCR)

Figure 3 Drug cycling with collateral sensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Differences between MC and AC

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Figure 1 Balance between proteasomal load and capacity

chemotherapy for patients with MC versus those with AC

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 NIR fluorescence is more suitable for

Figure 1 The dynamic nature of resistance mechanisms can be

Figure 4 Treatment plans using stereotactic body radiotherapy (SBRT)

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Median monthly launch price of a new anticancer drug,

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Frequency and overlap of alterations

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Fig. 5 EGFR mutation status of patients with NSCLC, detected by histological examination and ARMS PCR. EGFR mutation status of patients with NSCLC, detected.

Clinical courses of patients.

Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.

Figure 5 Schematic overview of a clinical decision-support

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Radiogenomics analysis can reveal relationships

Figure 2 Radiomics in cardiology

Figure 1 Overview of the imaging biomarker roadmap

Figure 3 Determination of the primary site

Empiric versus Site-Directed Chemotherapy in Cancer of Unknown Primary

Esteller, New England Journal of Medicine, 2008

Detection of somatic mutations in plasma allows for non-invasive real time therapy response monitoring of lung cancer patients José Carlos Machado.

Location of common clinically relevant mutations in EGFR

Nested RT-PCR of Mammaglobin and CK19 mRNA in plasma and circulating cells of controls (C) and patients (T) with breast cancer. Nested RT-PCR of Mammaglobin.

Figure 1 Gene-expression quantification methods

Prevalence of germline T790M.

Presentation transcript:

Figure 4 Example of a patients with CUP who received EPICUP-predicted matching site-specific treatment Figure 4 | Example of a patients with CUP who received EPICUP-predicted matching site-specific treatment. In this patient with CUP, for whom epigenetic profiling using EPICUP predicted a non-small-cell lung cancer (NSCLC) primary, a diagnosis validated by haematoxylin and eosin (H&E) staining; immunohistochemistry for the cytokeratins CK-7 (positive) and CK-20 (negative), and the specific lung marker homeobox protein Nkx-2.1 (TTF-1; positive); and real-time PCR specific for the G719X mutation in EGFR (positive), black lines: negative controls. This patient subsequently received treatment with the EGFR inhibitor erlotinib. Moran, S. et al. (2017) Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2017.97